United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
 - EconoTimes)
MONTREAL, May 01, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.
At the time of approval of EGRIFTA® on November 10, 2010, the FDA requested that the company conduct two large safety clinical trials.
The FDA determined that these two large-scale post-approval clinical trials are no longer required as the current labeling adequately reflects the safety profile of EGRIFTA®. The FDA also concluded that the size of the HIV patient population with lipodystrophy did not make such a requirement feasible.
In its most recent audited financial statements, for the year ended November 30, 2017, Theratechnologies estimated that the post-approval commitments would require an additional investment of US$13 million, which will no longer be required.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236
